Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS ClinicalTrials.gov record update

A Randomized, Double-Blind, Parallel Arm Study of the Efficacy and Safety of Two Doses of Dulaglutide in Combination With a Single Oral Antihyperglycemic Medication or as Monotherapy in Japanese Patients With Type 2 Diabetes Mellitus (AWARD-JPN: Assessment of Weekly Administration of LY2189265 in Diabetes - JAPAN)

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Open original source record ↗

Record identity and dates

Source
ClinicalTrials.gov
Source record ID
NCT04809220
Title field or adapter rule
protocolSection.identificationModule.officialTitle
Ingested At
2026-04-25T22:26:29.845142+00:00
Published At
2023-09-21T00:00:00+00:00
Record Updated At
2024-05-22
Results Posted At
2023-09-21
Timestamp Basis
source retrieval time was not retained by the feed adapter
Date limitation
source retrieval time was not retained by the feed adapter

Fields recorded by this source

protocolSection.conditionsModule.conditions
["Diabetes Mellitus", "Diabetes Mellitus, Type 2", "Glucose Metabolism Disorders", "Metabolic Disease", "Endocrine System Diseases", "Hypoglycemic Agents", "Type 2 Diabetes Mellitus (T2DM)"]
protocolSection.statusModule.lastUpdatePostDateStruct.date
"2024-05-22"
protocolSection.identificationModule.nctId
"NCT04809220"
protocolSection.identificationModule.officialTitle
"A Randomized, Double-Blind, Parallel Arm Study of the Efficacy and Safety of Two Doses of Dulaglutide in Combination With a Single Oral Antihyperglycemic Medication or as Monotherapy in Japanese Patients With Type 2 Diabetes Mellitus (AWARD-JPN: Assessment of Weekly Administration of LY2189265 in Diabetes - JAPAN)"
protocolSection.statusModule.overallStatus
"COMPLETED"
protocolSection.designModule.phases
["PHASE3"]
protocolSection.statusModule.resultsFirstPostDateStruct.date
"2023-09-21"

Study condition terms

  • Diabetes Mellitus (protocolSection.conditionsModule.conditions)
  • Diabetes Mellitus, Type 2 (protocolSection.conditionsModule.conditions)
  • Glucose Metabolism Disorders (protocolSection.conditionsModule.conditions)
  • Metabolic Disease (protocolSection.conditionsModule.conditions)
  • Endocrine System Diseases (protocolSection.conditionsModule.conditions)
  • Hypoglycemic Agents (protocolSection.conditionsModule.conditions)
  • Type 2 Diabetes Mellitus (T2DM) (protocolSection.conditionsModule.conditions)

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.